Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet the Editorial Board Member

Author(s): Yoshihiro Oka

Volume 29, Issue 29, 2022

Published on: 07 July, 2022

Page: [4891 - 4892] Pages: 2

DOI: 10.2174/092986732929220707160814

conference banner
Next »
[1]
Oka, Y.; Udaka, K.; Tsuboi, A.; Elisseeva, O.A.; Ogawa, H.; Aozasa, K.; Kishimoto, T.; Sugiyama, H. Cancer immunotherapy targeting wilms’ tumor gene WT1 product. J. Immunol., 2000, 164(4), 1873-1880.
[http://dx.doi.org/10.4049/jimmunol.164.4.1873] [PMID: 10657636]
[2]
Elisseeva, O.A. Oka, Y.; Tsuboi. A.; Ogata. K.; Wu, F.; Kim, E.H.; Soma, T.; Tamaki, H.; Kawakami, M.; Oji, Y.; Hosen, N.; Kubota, T.; Nakagawa, M.; Yamagami, T.; Hiraoka, A.; Tsukaguchi, M.; Udaka, K.; Ogawa, H.; Kishimoto, T.; Nomura, T.; Sugiyama, H. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood, 2002, 99(9), 3272-3279.
[http://dx.doi.org/10.1182/blood.v99.9.3272] [PMID: 11964293]
[3]
Oka, Y.; Tsuboi, A.; Murakami, M.; Hirai, M.; Tominaga, N.; Nakajima, H.; Elisseeva, O.A.; Masuda, T.; Nakano, A.; Kawakami, M.; Oji, Y.; Ikegame, K.; Hosen, N.; Udaka, K.; Yasukawa, M.; Ogawa, H.; Kawase, I.; Sugiyama, H. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol., 2003, 78(1), 56-61.
[http://dx.doi.org/10.1007/bf02983241] [PMID: 12894852]
[4]
Oka, Y.; Tsuboi, A.; Taguchi, T.; Osaki, T.; Kyo, T.; Nakajima, H.; Elisseeva, O.A.; Oji, Y.; Kawakami, M.; Ikegame, K.; Hosen, N.; Yoshihara, S.; Wu, F.; Fujiki, F.; Murakami, M.; Masuda, T.; Nishida, S.; Shirakata, T.; Nakatsuka, S.; Sasaki, A.; Udaka, K.; Dohy, H.; Aozasa, K.; Noguchi, S.; Kawase, I.; Sugiyama, H. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. USA, 2004, 101(38), 13885-13890.
[http://dx.doi.org/10.1073/pnas.0405884101] [PMID: 15365188]
[5]
Oka, Y.; Tsuboi, A.; Oji, Y.; Kawase, I.; Sugiyama, H. WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol., 2008, 20(2), 211-220.
[http://dx.doi.org/10.1016/j.coi.2008.04.009] [PMID: 18502632]
[6]
Nishida, S.; Ishikawa, T.; Egawa, S.; Koido, S.; Yanagimoto, H.; Ishii, J.; Kanno, Y.; Kokura, S.; Yasuda, H.; Oba, M.S.; Sato, M. Morimoto; S.; Fujiki, F.; Eguchi, H.; Nagano, H.; Kumanogoh, A.; Unno, M.; Kon, M.; Shimada, H.; Ito, K.; Homma, S.; Oka, Y.; Morita, S.; Sugiyama, H. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study. Cancer Immunol. Res., 2018, 6(3), 320-331.
[http://dx.doi.org/10.1158/2326-6066.cir-17-0386] [PMID: 29358173]
[7]
Nakata, J.; Nakajima, H.; Hayashibara, H.; Imafuku, K.; Morimoto, S.; Fujiki, F.; Motooka, D.; Okuzaki, D.; Hasegawa, K.; Hosen, N.; Tsuboi, A.; Oka, Y.; Kumanogoh, A.; Oji, Y.; Sugiyama, H. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget, 2018, 9(89), 36029-36038.
[http://dx.doi.org/10.18632/oncotarget.26338] [PMID: 30542516]

Rights & Permissions Print Cite
Article Metrics
9
© 2024 Bentham Science Publishers | Privacy Policy